Research Comparison

Cagrilintide vs Tirzepatide

In Short

Cagrilintide is long-acting amylin receptor agonist; Tirzepatide is gip / glp-1 dual-receptor agonist. Both are supplied as lyophilized powders for laboratory and in-vitro research use only. The table below compares their molecular data, half-life and research focus side by side.

	Cagrilintide	Tirzepatide
Classification	Long-acting amylin receptor agonist	GIP / GLP-1 dual-receptor agonist
Molecular formula	C194H312N54O59S2	C225H348N48O68
Molecular weight	4409.01 g/mol	4813.5 g/mol
CAS number	1415456-99-3	2023788-19-2
Research half-life	~7–9 days	~5 days
Primary research focus	Metabolic and glucose-regulation research	GIP/GLP-1 dual receptor agonist research
Form	Lyophilized powder	Lyophilized powder
Price from	$85.00	$50.00

Cagrilintide

Cagrilintide is a long-acting acylated amylin analogue engineered for extended receptor engagement at the amylin receptor complex (AMY1 and AMY3). Its mechanism involves activating calcitonin and amylin receptors in the area postrema and hypothalamus, modulating satiety signaling and gastric emptying. Compared to pramlintide, the only previously available amylin analogue, cagrilintide offers a substantially longer half-life (approximately 7 days vs. Research also indicates potential benefits in alcohol-related liver disease models, where amylin signaling may reduce hepatic lipid accumulation. The lyophilized powder should be stored at -20C prior to reconstitution with sterile water or bacteriostatic water; reconstituted solutions should be refrigerated at 2-8C. This compound is primarily studied by obesity research institutes, pharmaceutical laboratories investigating incretin-amylin synergy, and academic centers focused on appetite neurobiology and hepatic metabolism.

Full Cagrilintide research guide

Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both incretin pathways, it has been investigated in research models for effects on insulin secretion, glucagon suppression, gastric emptying, appetite signaling, and adipose tissue metabolism. It is frequently used as a comparator alongside GLP-1-only agonists such as semaglutide and triple agonists such as retatrutide in metabolic research. Supplied as a lyophilized powder for in-vitro and laboratory research use only; not for human consumption.

Full Tirzepatide research guide

Frequently Asked Questions

What is the main difference between Cagrilintide and Tirzepatide?

Cagrilintide is classified as long-acting amylin receptor agonist, while Tirzepatide is gip / glp-1 dual-receptor agonist. They are distinct research compounds with different mechanisms — the comparison table above sets out the molecular and pharmacokinetic differences side by side.

Can Cagrilintide and Tirzepatide be studied together?

Some research protocols evaluate related peptides in combination, and research blends exist. Combination study design depends entirely on the research question and model. Both compounds are supplied for laboratory and in-vitro research use only — not for human use.

Are Cagrilintide and Tirzepatide legal to buy for research?

Both are sold in the United States as research chemicals for laboratory and in-vitro use only. Neither is FDA-approved for human use. Researchers are responsible for compliance with all applicable regulations.

Buy Cagrilintide

From $85.00 — ≥98% HPLC, COA included.

Buy Tirzepatide

From $50.00 — ≥98% HPLC, COA included.

Research Use Only. This comparison summarizes published research. It is not medical advice. Neither compound is for human consumption or FDA-approved.